Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.

@article{Yuan2008EvaluationOT,
  title={Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.},
  author={Yong Yuan and Uchenna H. Iloeje and Joel Hay and Sammy Saab},
  journal={Journal of managed care pharmacy : JMCP},
  year={2008},
  volume={14 1},
  pages={21-33}
}
BACKGROUND As new treatment options for chronic hepatitis B virus (HBV) become available, evaluations of cost-effectiveness become important. Entecavir is a deoxyguanine nucleoside analogue approved by the U.S. Food and Drug Administration in March 2005 for HBV infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine aminotransferase or aspartate aminotransferase) or histologically active disease. Entecavir… CONTINUE READING
18 Extracted Citations
82 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 18 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 82 references

The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons

  • AR Levy, KV Kowdley, UH Iloeje
  • Value Health
  • 2007

Similar Papers

Loading similar papers…